Biosimilars: Evidential standards for health technology assessment

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 3, 2010, Pages 257-261

  Hughes, D A ^a  

^a BANGOR UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABSEAMED; ALPHEON; BIOGRASTIM; DOCETAXEL; DOXORUBICIN; HEXAL; HUMAN GROWTH HORMONE; HUMAN INSULIN; ISOPHANE INSULIN; LOW MOLECULAR WEIGHT HEPARIN; RATIOGRASTIM; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEVAGRASTIM; UNCLASSIFIED DRUG; ZARZIO;

BIOMEDICAL TECHNOLOGY ASSESSMENT; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG MANUFACTURE; GROWTH HORMONE DEFICIENCY; HEPATITIS C; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STANDARDIZATION;

ANIMALS; BIOLOGICAL PRODUCTS; BIOMEDICAL TECHNOLOGY; EVIDENCE-BASED MEDICINE; HUMANS; RECOMBINANT PROTEINS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 77149122380     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.112     Document Type: Review

References (21)

1. Lanthier, M., Behrman, R. & Nardinelli, C. Economic issues with follow-on protein products. Nat. Rev. Drug Discov. 7, 733-737 (2008).
2. Schneider, C.K. & Kalinke, U. Toward biosimilar monoclonal antibodies. Nat. Biotechnol. 26, 985-990 (2008).
3. Kresse, G.-B. Biosimilars-science, status, and strategic perspective. Eur. J. Pharm. Biopharm. 72, 479-486 (2009).
4. De Groot, A.S. & Scott, D.W. Immunogenicity of protein therapeutics. Trends Immunol. 28, 482-490 (2007).
5. Sorensen, P.S. et al. Danish Multiple Sclerosis Study Group. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362, 1184-1191 (2003).
6. Keithi-Reddy, S.R., Kandasamy, S., & Singh, A.K. Pure red cell aplasia due to follow-on epoetin. Kidney Int. 74, 1617-1622 (2008)
7. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 (2004).
8. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues. EMEA/CHMP/ BWP/49348/2005 (22 February 2006).
9. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Similar Biological Medicinal Products. CHMP/437/04 (30 October 2005).
10. Committee for Medicinal Products for Human Use. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. EMEA/CHMP/BMWP/14327/2006 (13 December 2007).
11. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. EMEA/CHMP/BMWP/42832/2005 (22 February 2006).
12. National Institute for Health and Clinical Excellence. Published Technology Appraisals. Accessed 28 April 2009.
13. Joint Formulary Committee. British National Formulary, 57th edn. (British Medical Association and Royal Pharmaceutical Society of Great Britain, London, 2009).
14. Scottish Medicines Consortium. Epoetin Zeta (Retacrit) for Treatment of Anaemia Associated with Chronic Renal Failure (2008). Accessed 28 April 2009.
15. Simoens, S. Interchangeability of off-patent medicines: a pharmacoeconomic perspective. Expert Rev. Pharmacoeconomics Outcomes Res. 8, 519-526 (2008).
16. Briggs, A.H. & O'Brien, B.J. The death of cost-minimization analysis? Health Econ. 10, 179-184 (2001).
17. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Comparability of Biotechnology-Derived Medicinal Products After a Change in the Manufacturing Process: Non-Clinical and Clinical Issues. EMEA/ CHMP/BMWP/101695/2006 (19 July 2007).
18. Bosmans, J.E., de Bruijne, M.C., van Hout, H.P., Hermens, M.L., Adèr, H.J. & van Tulder, M.W. Practical guidelines for economic evaluations alongside equivalence trials. Value Health 11, 251-258 (2008).
19. Horton, L.R. The European Experience with Follow-on Biologics Legislation. Federal Trade Commission Roundtable on Follow-on Biologic Drugs: Framework for Competition and Continued Innovation (21 November 2008).
20. Ferner, R.E., Hughes, D.A. & Aronson, J.K. NICE and new: appraising innovation. BMJ 340, b5493 (2010).
21. Medicines and Healthcare Products Regulatory Agency and the Commission on Human Medicines. Biosimilar products: what is biosimilar? Drug Safety Update. 1, 8 (2008).